Does My HRT or TRT Medical Director Need to Visit the Clinic in Person?

Direct answer

There is not one universal onsite schedule for every non-AHCA hormone practice. Appropriate onsite involvement depends on the clinic structure, services, procedures, staffing, medication handling, and applicable framework. MFMD uses a hybrid model — it does not use a remote-only model.

Open the full explanation3 sections and primary sources

Why does an initial in-person review help in HRT and TRT?

An in-person start lets the physician understand patient flow, medication storage, controlled-substance handling, injection workflow, pellet-procedure space (if applicable), provider/staff roles, escalation, and documentation — which matters more when a Schedule III controlled substance is involved.

How is ongoing governance handled after the initial visit?

Ongoing governance can be remote when appropriate, with onsite involvement when the clinic, services, or circumstances require it. For AHCA clinics, Medical Director pre-survey readiness stays focused on the physician-governance role rather than replacing the clinic’s AHCA consultant.

Owner takeaway

Remote governance can be useful, but the Medical Director should know the physical practice and be able to become onsite when it matters.

Primary sources

Review the cited source before applying the answer to a facility.

Separate the public question from the facility decision.

First confirm the facility type, AHCA or exemption status, payer model, licensed roster, and services. Then check the current official source and document who evaluates, prescribes, orders, administers, supervises, and escalates an exception.

MFMD can structure facility governance and present the proposed services and responsibilities to a physician. Clinical authority and acceptance remain with the reviewing physician.